Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H15N3O |
Molecular Weight | 253.2991 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN(C(C)=N1)C2=CC(C)=C3NC(=O)C=CC3=C2
InChI
InChIKey=NMNXBEXPAHSXOK-UHFFFAOYSA-N
InChI=1S/C15H15N3O/c1-9-6-13(18-8-10(2)16-11(18)3)7-12-4-5-14(19)17-15(9)12/h4-8H,1-3H3,(H,17,19)
Molecular Formula | C15H15N3O |
Molecular Weight | 253.2991 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Nanterinone [UK 61260], a phosphodiesterase III inhibitor, was undergoing II evaluation with Pfizer in the US for the treatment of heart failure. Nanterinone is a positive inotropic and balanced-type vasodilating drug, only partially based on phosphodiesterase III inhibition. Preliminary data from controlled studies suggest satisfactory long-term efficacy and safety.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. | 1989 Jul |
|
Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate. | 1995 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8842505
An oral dose of 2 mg nanterinone was studied in 14 patients with heart failure. All patients received placebo and nanterinone on 2 consecutive days.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:37:50 GMT 2023
by
admin
on
Fri Dec 15 15:37:50 GMT 2023
|
Record UNII |
1S169L7KAV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6327
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
C76889
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
102791-47-9
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
SUB09150MIG
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
1S169L7KAV
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
100000084446
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
DTXSID70145513
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL37971
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
C061526
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY | |||
|
71305
Created by
admin on Fri Dec 15 15:37:50 GMT 2023 , Edited by admin on Fri Dec 15 15:37:50 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |